{"id":"https://openalex.org/W7225424831","doi":"https://doi.org/10.3389/fphar.2026.1965457","title":"Cost-effectiveness of datopotamab deruxtecan versus chemotherapy as a first-line treatment for patients with advanced triple-negative breast cancer","display_name":"Cost-effectiveness of datopotamab deruxtecan versus chemotherapy as a first-line treatment for patients with advanced triple-negative breast cancer","publication_year":2026,"publication_date":"2026-11-06","ids":{"openalex":"https://openalex.org/W7225424831","doi":"https://doi.org/10.3389/fphar.2026.1965457"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.1965457","doi":"https://doi.org/10.3389/fphar.2026.1965457","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1965457","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1965457/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1965457/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5107280375","display_name":"Zuojuan Xiang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I139660479","display_name":"Central South University","ror":"https://ror.org/00f1zfq44","country_code":"CN","type":"education","lineage":["https://openalex.org/I139660479"]},{"id":"https://openalex.org/I4210115624","display_name":"Hunan Cancer Hospital","ror":"https://ror.org/025020z88","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210115624"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zuojuan Xiang","raw_affiliation_strings":["Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital","institution_ids":["https://openalex.org/I139660479","https://openalex.org/I4210115624"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5139879473","display_name":"Qiao Xia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I139660479","display_name":"Central South University","ror":"https://ror.org/00f1zfq44","country_code":"CN","type":"education","lineage":["https://openalex.org/I139660479"]},{"id":"https://openalex.org/I4210115624","display_name":"Hunan Cancer Hospital","ror":"https://ror.org/025020z88","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210115624"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Qiao Xia","raw_affiliation_strings":["Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital","institution_ids":["https://openalex.org/I139660479","https://openalex.org/I4210115624"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5161078326","display_name":"Zhengxiong Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I177388780","display_name":"Xuzhou Medical College","ror":"https://ror.org/04fe7hy80","country_code":"CN","type":"education","lineage":["https://openalex.org/I177388780"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Zhengxiong Li","raw_affiliation_strings":["School of Medical Informatics and Engineering, Xuzhou Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Medical Informatics and Engineering, Xuzhou Medical University","institution_ids":["https://openalex.org/I177388780"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5139879473","https://openalex.org/A5161078326"],"corresponding_institution_ids":["https://openalex.org/I139660479","https://openalex.org/I177388780","https://openalex.org/I4210115624"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/datopotamab-deruxtecan","display_name":"datopotamab deruxtecan","score":0.9980000257492065},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8659999966621399},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9470000267028809},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7129999995231628},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.6029999852180481},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.7850000262260437},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.875},{"id":"https://openalex.org/keywords/willingness-to-pay-threshold","display_name":"willingness-to-pay threshold","score":0.7319999933242798},{"id":"https://openalex.org/keywords/drug-pricing","display_name":"drug pricing","score":0.5839999914169312},{"id":"https://openalex.org/keywords/treatment-duration","display_name":"treatment duration","score":0.6320000290870667},{"id":"https://openalex.org/keywords/united-states","display_name":"United States","score":0.6589999794960022},{"id":"https://openalex.org/keywords/china","display_name":"China","score":0.9990000128746033},{"id":"https://openalex.org/keywords/partitioned-survival-model","display_name":"partitioned survival model","score":0.6859999895095825},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5479999780654907}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8208000063896179},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.7318000197410583},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6097999811172485},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5666000247001648},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.521399974822998},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.48500001430511475},{"id":"https://openalex.org/C188198153","wikidata":"https://www.wikidata.org/wiki/Q1613840","display_name":"Limiting","level":2,"score":0.4645000100135803},{"id":"https://openalex.org/C191935318","wikidata":"https://www.wikidata.org/wiki/Q148","display_name":"China","level":2,"score":0.43849998712539673},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4117000102996826},{"id":"https://openalex.org/C63479239","wikidata":"https://www.wikidata.org/wiki/Q7353546","display_name":"Robustness (evolution)","level":3,"score":0.4023999869823456},{"id":"https://openalex.org/C3018260909","wikidata":"https://www.wikidata.org/wiki/Q1322871","display_name":"Exploratory analysis","level":2,"score":0.390500009059906},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.36059999465942383},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.33379998803138733},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.33230000734329224},{"id":"https://openalex.org/C21200559","wikidata":"https://www.wikidata.org/wiki/Q7451068","display_name":"Sensitivity (control systems)","level":2,"score":0.3264999985694885},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.3260999917984009},{"id":"https://openalex.org/C85973986","wikidata":"https://www.wikidata.org/wiki/Q1091731","display_name":"Exploratory research","level":2,"score":0.31690001487731934},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.30730000138282776},{"id":"https://openalex.org/C28761237","wikidata":"https://www.wikidata.org/wiki/Q7805321","display_name":"Time horizon","level":2,"score":0.29980000853538513},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.29910001158714294},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.2973000109195709},{"id":"https://openalex.org/C6964187","wikidata":"https://www.wikidata.org/wiki/Q659256","display_name":"Indirect costs","level":2,"score":0.2770000100135803},{"id":"https://openalex.org/C138816342","wikidata":"https://www.wikidata.org/wiki/Q189603","display_name":"Public health","level":2,"score":0.27219998836517334},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.260699987411499},{"id":"https://openalex.org/C2986637895","wikidata":"https://www.wikidata.org/wiki/Q953865","display_name":"Breast tumor","level":4,"score":0.2549000084400177}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3389/fphar.2026.1965457","doi":"https://doi.org/10.3389/fphar.2026.1965457","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1965457","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1965457/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:d93de5246ea346a6924162ee2ae9f5d3","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/d93de5246ea346a6924162ee2ae9f5d3","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.1965457","doi":"https://doi.org/10.3389/fphar.2026.1965457","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1965457","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1965457/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225424831.pdf","grobid_xml":"https://content.openalex.org/works/W7225424831.grobid-xml"},"referenced_works_count":36,"referenced_works":["https://openalex.org/W1982967337","https://openalex.org/W2020677481","https://openalex.org/W2058056848","https://openalex.org/W2519603001","https://openalex.org/W3022747490","https://openalex.org/W3041386602","https://openalex.org/W3134417189","https://openalex.org/W3138073345","https://openalex.org/W3138275639","https://openalex.org/W3159031217","https://openalex.org/W3212351175","https://openalex.org/W4319875143","https://openalex.org/W4366235587","https://openalex.org/W4382631651","https://openalex.org/W4385475922","https://openalex.org/W4389209433","https://openalex.org/W4391454183","https://openalex.org/W4395053564","https://openalex.org/W4396597278","https://openalex.org/W4402754931","https://openalex.org/W4407131929","https://openalex.org/W4408591305","https://openalex.org/W4409019592","https://openalex.org/W4410548685","https://openalex.org/W4412980310","https://openalex.org/W7117458667","https://openalex.org/W7118079722","https://openalex.org/W7124872739","https://openalex.org/W7127593600","https://openalex.org/W7128957083","https://openalex.org/W7131243145","https://openalex.org/W7133216968","https://openalex.org/W7139911376","https://openalex.org/W7149012512","https://openalex.org/W7159600154","https://openalex.org/W7162584865"],"related_works":["https://openalex.org/W7162068825","https://openalex.org/W4410548685","https://openalex.org/W4389219600","https://openalex.org/W4386127376","https://openalex.org/W7134138189","https://openalex.org/W4412980310","https://openalex.org/W7203626303","https://openalex.org/W4362466868","https://openalex.org/W4382786985","https://openalex.org/W4307021407"],"abstract_inverted_index":{"Background":[0],"The":[1,80,283],"phase":[2],"III":[3],"TROPION-Breast02":[4,60],"trial":[5],"demonstrated":[6],"improved":[7],"progression-free":[8],"and":[9,47,66,70,77,104,109,114,120,135,154,170,185,254,299],"overall":[10],"survival":[11,55,183],"with":[12,20,62,128,245,264],"datopotamab":[13],"deruxtecan":[14],"(Dato-DXd)":[15],"versus":[16],"chemotherapy":[17,265],"in":[18,101,106,139,167,172,193,211,220,232,236,266],"patients":[19],"previously":[21],"untreated":[22],"advanced":[23],"triple-negative":[24],"breast":[25],"cancer":[26],"who":[27],"were":[28,72,99,124,152,174,188,276],"ineligible":[29],"for":[30],"immunotherapy.":[31],"This":[32],"study":[33],"evaluated":[34],"the":[35,40,43,84,102,115,118,140,149,168,178,189,205,221,237,246,251,256],"cost-effectiveness":[36,86,180],"of":[37,42,117,145,160,164,287,296],"Dato-DXd":[38,130,186,222,259],"from":[39,74,224],"perspectives":[41],"United":[44],"States":[45],"(U.S.)":[46],"Chinese":[48],"healthcare":[49],"systems.":[50],"Methods":[51],"A":[52],"three-state":[53],"partitioned":[54],"model":[56],"was":[57,83,260],"developed":[58],"using":[59],"data,":[61],"a":[63,217],"10-year":[64],"horizon":[65],"21-day":[67],"cycles.":[68],"Costs":[69],"utilities":[71],"obtained":[73],"public":[75],"databases":[76],"published":[78],"literature.":[79],"primary":[81],"outcome":[82],"incremental":[85],"ratio":[87],"(ICER),":[88],"expressed":[89],"as":[90],"cost":[91],"per":[92],"quality-adjusted":[93],"life-year":[94],"(QALY)":[95],"gained.":[96],"Willingness-to-pay":[97],"thresholds":[98],"$150,000/QALY":[100],"U.S.":[103,169,238],"$27,906/QALY":[105],"China.":[107],"Sensitivity":[108],"scenario":[110,199],"analyses":[111,123,241],"assessed":[112],"uncertainty":[113],"robustness":[116],"findings,":[119],"exploratory":[121,198],"subgroup":[122,240],"performed.":[125],"Results":[126,275],"Compared":[127],"chemotherapy,":[129],"increased":[131],"costs":[132],"by":[133,137],"$565,572.29":[134],"QALYs":[136],"0.44":[138],"U.S.,":[141],"yielding":[142,157],"an":[143,158],"ICER":[144,159],"$1,287,001.65/QALY.":[146],"In":[147,197],"China,":[148],"corresponding":[150],"increases":[151],"$39,052.50":[153],"0.42":[155],"QALYs,":[156],"$92,640.82/QALY.":[161],"Price":[162,269],"reductions":[163,270],"approximately":[165],"62.43%":[166],"28.83%":[171],"China":[173,233],"required":[175],"to":[176,204,226,278],"reach":[177],"respective":[179],"thresholds.":[181],"Progression-free":[182],"utility":[184],"price":[187],"most":[190],"influential":[191],"parameters":[192],"one-way":[194],"sensitivity":[195],"analyses.":[196],"analyses,":[200],"limiting":[201],"treatment":[202,281],"duration":[203],"reported":[206],"median":[207],"yielded":[208,242],"cost-effective":[209,231,262],"results":[210],"both":[212],"countries.":[213],"Assuming":[214],"unchanged":[215],"efficacy,":[216],"hypothetical":[218],"reduction":[219],"dose":[223],"6":[225],"4":[227],"mg/kg":[228],"made":[229],"it":[230],"but":[234],"not":[235,261],"Exploratory":[239],"conclusions":[243],"consistent":[244],"base-case":[247,257],"findings.":[248],"Conclusion":[249],"At":[250],"modeled":[252],"prices":[253],"under":[255],"assumptions,":[258],"compared":[263],"either":[267],"country.":[268],"could":[271],"improve":[272],"its":[273],"cost-effectiveness.":[274],"sensitive":[277],"assumptions":[279],"about":[280],"duration.":[282],"potential":[284],"economic":[285],"benefits":[286],"reduced-dose":[288],"or":[289],"fixed-duration":[290],"strategies":[291],"depend":[292],"on":[293],"clinical":[294],"confirmation":[295],"maintained":[297],"efficacy":[298],"acceptable":[300],"safety.":[301]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-11-07T00:00:00"}